<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="153">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002807</nctid>
  <trial_identification>
    <studytitle>Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery</studytitle>
    <scientifictitle>A Phase III Randomized Trial Comparing TAH BSO Versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk Carcinoma of the Endometrium</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CAN-NCIC-EN5</secondaryid>
    <secondaryid>EN5</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - radiation therapy

No Intervention: Observation - 

Experimental: Radiation - Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)


Treatment: other: radiation therapy
45 Gy in 25 fractions over 5 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival (combined with the ASTEC trial)</outcome>
      <timepoint>2009</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>2009</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically proven adenocarcinoma or adenosquamous cell carcinoma of the
             endometrium

               -  Intermediate-risk of recurrence after laparoscopically-assisted vaginal
                  hysterectomy (with or without laparoscopic staging) or total abdominal
                  hysterectomy and bilateral salpingo-oophorectomy

               -  Postoperative pathologic stage IA/IB (grade 3), stage IC (grade 1-3), or stage
                  IIA (all grades)

          -  Patients with more than 50% myometrial invasion (grade 1 or 2) or less than 50%
             myometrial invasion (grade 3) but with positive peritoneal cytology also eligible

               -  Patients whose sole criterion for increased risk is positive peritoneal cytology
                  are not eligible

          -  No pathologically involved lymph nodes if staging procedure performed

          -  Stage I papillary serous or clear cell endometrial cancer allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  ECOG 0-3

        Life expectancy:

          -  At least 3 years

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine less than 2 times upper limit of normal

          -  No serious renal disease that would preclude radiotherapy

        Cardiovascular:

          -  No serious cardiovascular disease that would preclude radiotherapy

        Other:

          -  No history of inflammatory bowel disease such as ulcerative colitis

          -  No other malignancy within past 5 years except curatively treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, colon cancer, or thyroid
             cancer

          -  No psychiatric or addictive disorder that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  No prior anticancer hormonal therapy

          -  No concurrent progestogens

        Radiotherapy:

          -  No prior pelvic irradiation

          -  No prior or other concurrent vaginal intracavitary radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No prior anticancer therapy

          -  No other concurrent anticancer therapy</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>120</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/1996</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>116</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Women's Hospital - Carlton</hospital>
    <postcode>3053 - Carlton</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>NCIC Clinical Trials Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet
      known whether radiation therapy is more effective than observation only after sugery in
      treating endometrial cancer.

      PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
      works compared to observation only in treating patients with stage I or stage II endometrial
      cancer who have undergone hysterectomy and oophorectomy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002807</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Himu R. Lukka, MD</name>
      <address>Margaret and Charles Juravinski Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>